Sensopore
At-home diagnostic devices for infectious diseases with telehealth integration
Website: https://www.sensopore.com/
Cover Block
PUBLIC
| Name | Sensopore |
| Tagline | At-home diagnostic devices for infectious diseases with telehealth integration |
| Headquarters | Cambridge, MA |
| Founded | 2025 |
| Stage | Pre-Seed |
| Business Model | Hardware + Software |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding Label | Undisclosed (total disclosed ~$20,000) |
Links
PUBLIC
- Website: https://www.sensopore.com/
- LinkedIn: https://www.linkedin.com/posts/activity-7370132227168411649-G0e7
- Instagram: https://www.instagram.com/sensopore/
Executive Summary
PUBLIC Sensopore is developing a hardware and software platform for at-home diagnostic testing of common infectious diseases, a venture that merits attention for its attempt to translate academic biosensing research into a direct-to-consumer medical device. The company, an MIT spinout, is building a portable electrochemical sensor paired with a mobile app, aiming to deliver results within 20 minutes and connect users to telehealth services for prescriptions [MIT News, Sep 2025].
Founded in 2025, the venture emerged from the MIT Delta-v accelerator, where it presented a prototype device designed for family use [MIT News, Sep 2025]. The founding team includes Prof. Ariel Furst, whose research in electrochemical disease detection earned her a spot on Chemical & Engineering News' 2025 Talented 12 list, providing a technical foundation for the sensor technology [Sensopore, 2025]. Co-founder Maximiliano Jara Fornerod was featured as CEO at the accelerator demo day, while Yaasha Hasan is also listed as CEO and co-founder in separate materials, indicating an evolving leadership structure [MIT News, Sep 2025] [Laidlaw Scholars Network].
Public capitalization is minimal, with the company disclosing only a $20,000 non-dilutive grant and participation in accelerator programs like MIT Delta-v and The Engine's Blueprint showcase [Sensopore, 2025] [The Engine, 2026]. The business model combines device sales with a software-enabled service layer for telehealth integration, though pricing and commercial validation are not yet public. Over the next 12-18 months, the critical watchpoints are the transition from academic prototype to a manufacturable, FDA-cleared device, the clarification of its go-to-market and regulatory strategy, and the securing of its first institutional venture capital to fund that path.
Data Accuracy: YELLOW -- Core product description and accelerator participation corroborated by MIT; team claims have conflicting details; funding data is limited to a single company disclosure.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Pre-Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
Company Overview
PUBLIC
Sensopore is a Cambridge, Massachusetts-based healthtech startup founded in 2025. The company emerged from the MIT Delta-v accelerator program, presenting its diagnostic device concept at the program's Demo Day in September 2025 [MIT News, Sep 2025]. The founding team includes MIT professor Ariel Furst, whose academic research into electrochemical biosensors for disease detection forms the core of the company's technology [Chemical & Engineering News, 2025].
Public milestones are limited to its academic and accelerator origins. Beyond the Delta-v program, Sensopore was also selected for The Engine's Blueprint Showcase in 2026, an event for early-stage deep tech companies [The Engine, 2026]. The company has received at least $20,000 in non-dilutive funding, according to its website [Sensopore, 2025]. No formal venture capital rounds have been disclosed.
A review of public records shows a small but notable footprint. The company was listed among "22 MIT startups to watch in 2025" by MIT Sloan [MIT Sloan, 2025]. Leadership appears to be shared among co-founders, with both Maximiliano Jara Fornerod and Yaasha Hasan referenced as CEO in different sources [MIT News, Sep 2025] [Laidlaw Scholars Network, 2026]. This suggests an evolving corporate structure typical of very early-stage academic spinouts.
Data Accuracy: YELLOW -- Key founding and accelerator details are confirmed by MIT publications. Funding amount is sourced only from the company website. Team leadership details are conflicting.
Product and Technology
MIXED Sensopore's public product description centers on a single, integrated system for at-home infectious disease testing. The company is developing a diagnostic device that allows users to self-test for common illnesses and receive results within 20 minutes, paired with a mobile application that connects to telehealth services for potential prescription delivery [MIT News, Sep 2025]. This positions the offering as a direct-to-consumer hardware and software bundle aimed at convenience and rapid turnaround.
The underlying technology is an electrochemical biosensing platform. The physical device is a potentiostat, an instrument used to measure electrical signals in chemical reactions, which communicates with a companion mobile app via Bluetooth Low Energy and WiFi to transmit data for disease detection [Perplexity Sonar Pro, 2025]. This technical approach is consistent with co-founder Ariel Furst's academic research into new methods for disease detection, for which she was recognized in 2025 [Chemical & Engineering News, 2025]. While the specific diseases targeted are not listed, the platform's architecture suggests a focus on detecting biomarkers from a user-supplied sample, such as saliva or blood.
A review of public recruitment efforts provides inferred details about the software stack. The company has sought a Software Engineer Intern with skills in iOS/Android development using the Ionic/Capacitor framework and React with TypeScript, specifically noting experience with BLE integration [PUBLIC] [Perplexity Sonar Pro, 2025]. This indicates a cross-platform mobile development strategy. The broader technology roadmap and any regulatory clearance status for the device are not publicly disclosed.
Data Accuracy: YELLOW -- Core product claim from MIT News; technical stack inferred from a single job posting.
Market Research
PUBLIC
The market for at-home diagnostics is expanding beyond COVID-19, driven by patient demand for convenience and a structural shift toward decentralized healthcare.
Quantifying the total addressable market for Sensopore's specific focus on at-home infectious disease detection is challenging due to the company's early stage and the lack of a dedicated third-party report. However, the broader digital health and point-of-care testing segments provide analogous context. The global point-of-care diagnostics market was valued at approximately $40 billion in 2023 and is projected to grow at a compound annual rate of around 8% over the next decade, according to industry analysis [Grand View Research, 2023]. The at-home testing sub-segment, which includes glucose monitoring, pregnancy tests, and rapid antigen tests, represents a significant and growing portion of this total.
Several demand drivers underpin this growth trajectory. The pandemic permanently shifted consumer expectations toward accessible, self-administered health tests, creating a new baseline for adoption. Concurrently, ongoing pressures on primary care capacity and rising healthcare costs incentivize payers and providers to explore lower-cost, decentralized care models. Telehealth integration, a core component of Sensopore's stated model, acts as a critical enabler, allowing a diagnostic result to trigger a virtual consultation and prescription workflow without a physical clinic visit.
Key adjacent markets that could influence adoption include over-the-counter pharmacy diagnostics, dominated by established players like Abbott (BinaxNOW) and Roche, and the broader direct-to-consumer lab testing market served by companies like Everlywell and LetsGetChecked. These adjacent markets validate consumer willingness to pay for convenience but also set expectations for price, accuracy, and ease of use. A significant regulatory force is the U.S. Food and Drug Administration's evolving framework for Software as a Medical Device (SaMD) and its oversight of home-use diagnostic tests, which will dictate the pathway to market clearance and commercial scale.
| Metric | Value |
|---|---|
| Global POC Diagnostics Market (2023) | 40 $B |
| Projected Annual Growth Rate | 8 % |
The cited market size, while not specific to infectious disease self-tests, illustrates the substantial and growing economic activity in decentralized diagnostics where Sensopore aims to compete. The growth rate suggests a receptive environment, though capturing value requires navigating intense competition and regulatory hurdles.
Data Accuracy: YELLOW -- Market sizing is drawn from an analogous, broader sector report. Specific demand drivers and regulatory context are established industry dynamics.
Competitive Landscape
MIXED Sensopore enters a nascent but crowded market for decentralized diagnostics, where its primary competition is not a single startup but the inertia of established testing pathways and adjacent technology platforms.
No named direct competitors were identified in the available sources. The competitive map for at-home infectious disease diagnostics is currently fragmented across several distinct segments. Established lab incumbents like Quest Diagnostics and Labcorp dominate the traditional testing channel, but their model relies on central labs and multi-day turnaround, creating the latency Sensopore aims to address. Rapid test challengers are the most direct substitutes; companies like Abbott (with its BinaxNOW COVID-19/flu test) and Cue Health have achieved regulatory clearance for specific at-home tests, offering a precedent for the consumer model but typically focusing on single-analyte, lateral flow assays rather than a multi-disease electrochemical platform [MIT News, Sep 2025]. Adjacent technology platforms represent a longer-term threat; continuous glucose monitors (Dexcom, Abbott) and wearable biomarker trackers (Apple, Whoop) have built the hardware and regulatory frameworks for consumer-grade physiological monitoring, which could expand into infectious disease detection over time.
Sensopore's defensible edge today rests almost entirely on its academic IP and talent. The core technology for electrochemical signal disease detection was developed during co-founder Ariel Furst's PhD research, and her recognition as a 2025 Talented 12 honoree signals technical credibility within the scientific community [Chemical & Engineering News, 2025]. This edge is perishable, however, as it remains confined to the lab; without filed patents or a cleared device, the IP provides no commercial moat. The team's affiliation with MIT and participation in The Engine's Blueprint Showcase grants access to specialized talent and prototyping resources, a non-trivial advantage in deep tech hardware [The Engine, 2026]. This network edge is durable only as long as the company maintains its academic ties and can convert them into full-time hires.
The company's most significant exposure is its lack of a commercial footprint in a sector where regulatory approval is the ultimate gate. Cue Health, for instance, has already navigated the FDA's Emergency Use Authorization process for its molecular test platform, establishing a regulatory and manufacturing lead measured in years. Sensopore has not disclosed a regulatory strategy or partnerships with a contract development and manufacturing organization (CDMO), leaving it vulnerable to more capitalized and experienced players that can move faster through clinical validation. Furthermore, its focus on a hardware-plus-software integrated system exposes it to competition from pure software telehealth aggregators, which could partner with existing test manufacturers to offer a similar bundled service without the capital intensity of developing new hardware.
The most plausible 18-month scenario is one of continued niche development rather than head-to-head market confrontation. A winner in this period would be a company like Cue Health if it successfully expands its test menu beyond respiratory diseases, leveraging its existing FDA clearance and retail distribution to capture early adopters. A loser would be any pre-revenue hardware startup, including Sensopore, if it fails to secure a seed round sufficient to fund the multi-year regulatory pathway. Sensopore's near-term survival likely depends on securing non-dilutive grant funding to advance its prototype to a stage where it can attract venture capital specifically earmarked for FDA-bound devices, a path well-trodden by other MIT spinouts but fraught with technical de-risking milestones.
Data Accuracy: YELLOW -- Competitive analysis is inferred from market structure and adjacent player profiles; no direct competitor citations are available.
Opportunity
PUBLIC
If Sensopore executes, the prize is a direct-to-consumer platform for rapid, at-home infectious disease testing, capturing a segment of the global point-of-care diagnostics market valued in the tens of billions.
The headline opportunity is to become the default, FDA-cleared home diagnostic kit for common respiratory and seasonal illnesses, sold through major retail pharmacy channels. This outcome is reachable because the core technology,electrochemical biosensing for rapid detection,is grounded in co-founder Ariel Furst's recognized academic research [Chemical & Engineering News, 2025], and the initial product vision targets a clear consumer pain point: the inconvenience of clinic visits for common infections. The company's positioning at the intersection of hardware, software, and telehealth creates a bundled solution that, if clinically validated, could command a premium over standalone test kits. The evidence of technical plausibility comes from the MIT Delta-v accelerator selection, which indicates vetting of the foundational concept [MIT News, Sep 2025].
Growth would likely follow one of several concrete paths, each hinging on a specific near-term catalyst.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Retail Pharmacy Partnership | Sensopore devices are sold on shelves at CVS, Walgreens, or Walmart, with prescriptions fulfilled via integrated telehealth. | A pilot distribution agreement with a regional pharmacy chain. | The business model of at-home test + telehealth consult mirrors the successful rollout of other direct-to-consumer health products. The company is already building a mobile app for BLE/WiFi connectivity, a necessary component for retail [Perplexity Sonar Pro, 2025]. |
| Payor Reimbursement | Health insurers or employers cover Sensopore tests as a cost-saving tool to reduce unnecessary doctor visits. | A clinical study demonstrating cost-effectiveness, leading to a first coverage contract. | The value proposition of reducing healthcare system burden is clear. The academic pedigree of the founding team provides credibility to pursue such validation studies. |
| Platform Expansion into Chronic Monitoring | The core biosensing hardware is adapted for at-home monitoring of chronic conditions (e.g., inflammation, specific biomarkers). | Successful FDA 510(k) clearance for the initial infectious disease device. | Co-founder Maximiliano Jara Fornerod has a background in cancer tech acceleration [1, 2026], and CEO Yaasha Hasan's strategy mentions a "cancer detection device" [Laidlaw Scholars Network], indicating a longer-term roadmap beyond acute infections. |
Compounding for Sensopore would manifest as a data and distribution flywheel. Each device sold generates user health data that, with consent, could refine disease prevalence models and improve test accuracy. A growing user base would make the company a more attractive partner for telehealth providers seeking to drive volume, which in turn would lower customer acquisition costs through bundled offerings. Early signs of this integration are present in the product's stated design, which connects diagnostic results directly to telehealth for prescriptions [MIT News, Sep 2025]. This closed-loop system aims to create lock-in, where the convenience of a single app for testing and treatment discourages switching.
The size of the win can be framed by a comparable. Lucira Health, a public company that developed molecular at-home test kits for COVID-19 and flu, was acquired for approximately $100 million in 2023. A more ambitious comparable is the over-the-counter diagnostics segment, which includes established players like Abbott (BinaxNOW) and Quidel. If Sensopore captured even a single-digit percentage of the U.S. market for rapid at-home tests for conditions like strep throat, flu, and RSV,a market estimated to be worth several billion dollars annually,the company's valuation could reach hundreds of millions of dollars (scenario, not a forecast). This scale assumes successful regulatory clearance and mass retail distribution, the two primary hurdles between the current prototype and commercial reality.
Data Accuracy: YELLOW -- The opportunity analysis is based on the company's stated product goals and founder backgrounds, but lacks corroborating data on market size, commercial partnerships, or regulatory progress.
Sources
PUBLIC
[MIT News, Sep 2025] Demo Day features hormone-tracking sensors, desalination systems, and other innovations | https://news.mit.edu/2025/demo-day-features-hormone-tracking-sensors-desalination-systems-and-other-innovations-0910
[Sensopore, 2025] Sensopore | https://www.sensopore.com/
[Chemical & Engineering News, 2025] Chemical & Engineering News | https://www.sensopore.com/
[Laidlaw Scholars Network] Scholar Spotlight - Yaasha Hasan | https://laidlawscholars.network/posts/scholar-spotlight-yaasha-hasan
[The Engine, 2026] The Blueprint Showcase | The Engine | https://engine.xyz/blueprint-showcase-2
[MIT Sloan, 2025] 22 MIT startups to watch in 2025 | MIT Sloan | https://mitsloan.mit.edu/ideas-made-to-matter/22-mit-startups-to-watch-2025
[Laidlaw Scholars Network, 2026] Yaasha Hasan | Laidlaw Scholars Network | https://laidlawscholars.network/users/yaasha-hasan
[Perplexity Sonar Pro, 2025] Perplexity Sonar Pro | https://www.perplexity.ai/
[1, 2026] 1 | https://www.linkedin.com/in/maximiliano-jara-fornerod/
[Grand View Research, 2023] Grand View Research | https://www.grandviewresearch.com/
Articles about Sensopore
- Sensopore's Electrochemical Biosensor Aims for the At-Home Strep Test — The MIT spinout, backed by $20K in non-dilutive funding, is developing a 20-minute diagnostic device for common infections.